Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Total Assets of $697.5 thousand for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $697.5K | -30.7% |
| 2024 | $1.01M | -30.5% |
| 2023 | $1.45M | -28.9% |
| 2022 | $2.04M | -42.0% |
| 2021 | $3.51M | +496.3% |
| 2020 | $589.2K | -60.1% |
| 2019 | $1.48M | -25.7% |
| 2018 | $1.99M | -42.1% |
| 2017 | $3.44M | -38.8% |
| 2016 | $5.61M | -72.5% |
| 2015 | $20.44M | -21.9% |
| 2014 | $26.18M | +30.9% |
| 2013 | $20.01M | +222.5% |
| 2012 | $6.20M | -53.5% |
| 2011 | $13.35M | -7.3% |
| 2010 | $14.40M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $419.9K | -47.6% | -41.9% |
| June 30, 2025 | $722.4K | -15.7% | +8.4% |
| March 31, 2025 | $666.3K | -38.3% | -33.8% |
| December 31, 2024 | $1.01M | -30.5% | +25.5% |
| September 30, 2024 | $802.0K | -52.5% | -6.4% |
| June 30, 2024 | $856.4K | -49.2% | -20.6% |
| March 31, 2024 | $1.08M | -37.3% | -25.5% |
| December 31, 2023 | $1.45M | -28.9% | -14.3% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -30.7% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s total assets has declined by 95.2% (from $14.40 million to $697.5 thousand).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: